Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Queensland Health
Baxter
US Department of Justice
Argus Health
Teva
Federal Trade Commission
McKesson
Express Scripts
Novartis

Generated: January 23, 2018

DrugPatentWatch Database Preview

PRELAY Drug Profile

« Back to Dashboard

Which patents cover Prelay, and when can generic versions of Prelay launch?

Prelay is a drug marketed by Sankyo and is included in one NDA. There are two patents protecting this drug.

This drug has forty-eight patent family members in thirty-six countries.

The generic ingredient in PRELAY is troglitazone. Additional details are available on the troglitazone profile page.
Summary for PRELAY
International Patents:48
US Patents:2
Applicants:1
NDAs:1
Bulk Api Vendors: 58
Patent Applications: 4,478
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PRELAY at DailyMed
Drug patent expirations by year for PRELAY

US Patents and Regulatory Information for PRELAY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sankyo PRELAY troglitazone TABLET;ORAL 020719-001 Jan 29, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-003 Aug 4, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-001 Jan 29, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-003 Aug 4, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-002 Jan 29, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-002 Jan 29, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PRELAY

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sankyo PRELAY troglitazone TABLET;ORAL 020719-002 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-003 Aug 4, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-001 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-003 Aug 4, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-002 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-003 Aug 4, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-001 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-003 Aug 4, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-002 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Sankyo PRELAY troglitazone TABLET;ORAL 020719-002 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Premature patent expiration for: PRELAY

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
➤ Subscribe PRELAY ➤ Subscribe
➤ Subscribe PRELAY ➤ Subscribe

Non-Orange Book US Patents for PRELAY

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,972,973 Sulfonylurea-glitazone combinations for diabetes ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for PRELAY

Supplementary Protection Certificates for PRELAY

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB97/084 United Kingdom ➤ Subscribe PRODUCT NAME: TROGLITAZONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 10949/0277 19970729; UK 10949/0278 19970729; UK 10949/0279 19970729; UK 06384/0005 19970729; UK 06384/0006 19970729; UK 06384/0007 19970729
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Healthtrust
Daiichi Sankyo
QuintilesIMS
Novartis
Colorcon
Cerilliant
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot